Transcode Therapeutics, Inc. (RNAZ) stock
RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.35+0.03 (+2.27%)
Close on Nov 16, 2026Market cap $1.37MP/E –Yield –
Transcode Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Transcode Therapeutics's total assets was $151.01M at Jun 30, 2026. For fiscal 2025 it was $162.40M, up 2126.3% from the year before. The highest annual figure on record is $162.40M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $162.40M | +2126.3% |
| FY2024 | Dec 31, 2024 | $7.29M | +41.1% |
| FY2023 | Dec 31, 2023 | $5.17M | -31.9% |
| FY2022 | Dec 31, 2022 | $7.59M | -66.9% |
| FY2021 | Dec 31, 2021 | $22.94M | +2073.5% |
| FY2020 | Dec 31, 2020 | $1.06M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $151.01M | +1726.8% |
| Q1 FY2026 | Mar 31, 2026 | $157.16M | +1091.2% |
| Q4 FY2025 | Dec 31, 2025 | $162.40M | +2126.3% |
| Q3 FY2025 | Sep 30, 2025 | $5.23M | +32.8% |
| Q2 FY2025 | Jun 30, 2025 | $8.27M | +71.3% |
| Q1 FY2025 | Mar 31, 2025 | $13.19M | +81.0% |
| Q4 FY2024 | Dec 31, 2024 | $7.29M | +41.1% |
| Q3 FY2024 | Sep 30, 2024 | $3.94M | -61.5% |
| Q2 FY2024 | Jun 30, 2024 | $4.82M | -18.0% |
| Q1 FY2024 | Mar 31, 2024 | $7.29M | +30.4% |
| Q4 FY2023 | Dec 31, 2023 | $5.17M | -31.9% |
| Q3 FY2023 | Sep 30, 2023 | $10.23M | -14.9% |
| Q2 FY2023 | Jun 30, 2023 | $5.88M | -58.5% |
| Q1 FY2023 | Mar 31, 2023 | $5.59M | -70.3% |
| Q4 FY2022 | Dec 31, 2022 | $7.59M | -66.9% |
| Q3 FY2022 | Sep 30, 2022 | $12.02M | -52.6% |
| Q2 FY2022 | Jun 30, 2022 | $14.16M | +829.9% |
| Q1 FY2022 | Mar 31, 2022 | $18.85M | +1686.1% |
| Q4 FY2021 | Dec 31, 2021 | $22.94M | – |
| Q3 FY2021 | Sep 30, 2021 | $25.36M | – |
| Q2 FY2021 | Jun 30, 2021 | $1.52M | – |
| Q4 FY2020 | Dec 31, 2020 | $1.06M | – |
See a number that looks wrong?